Literature DB >> 22350404

A case of splenic infarction possibly attributable to Mycoplasma pneumoniae infection without accompanying pneumonia.

Seung Jin Park1, Yu Min Lee, Chang Hoon Lee, Ji Hyun Cho, Jae Hoon Lee.   

Abstract

We report a case of a patient with splenic infarction possibly attributable to Mycoplasma pneumoniae infection without accompanying pneumonia. A 24-year-old man was admitted to our hospital with a 7-day history of fever, sore throat, and left upper-quadrant abdominal pain. Chest radiography revealed no active lung lesions; however, abdominal computed tomography showed hepatosplenomegaly with splenic infarction. At the time of admission, the patient's serum IgM titer for M. pneumoniae was 79.7 U/mL (positive titer >70 U/mL). Two weeks later, the serum IgM titer for M. pneumoniae had markedly increased to 3,158.1 U/mL. The patient was treated with azithromycin, and his symptoms began to improve. After 5 weeks, the spleen size decreased, and a scar was observed at the site of the infarct.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350404     DOI: 10.1007/s10156-012-0390-y

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  3 in total

1.  Analysis of the risk factors and clinical features of Mycoplasma pneumoniae pneumonia with embolism in children: a retrospective study.

Authors:  Chunjiao Han; Tongqiang Zhang; Jiafeng Zheng; Peng Jin; Qi Zhang; Wei Guo; Yongsheng Xu
Journal:  Ital J Pediatr       Date:  2022-08-20       Impact factor: 3.288

Review 2.  Thrombosis associated with mycoplasma pneumoniae infection (Review).

Authors:  Jingwei Liu; Yumei Li
Journal:  Exp Ther Med       Date:  2021-07-07       Impact factor: 2.447

3.  The Level of D-Dimer Is Positively Correlated With the Severity of Mycoplasma pneumoniae Pneumonia in Children.

Authors:  Yan Zheng; Lingling Hua; Qiannan Zhao; Mengyao Li; Meixia Huang; Yunlian Zhou; Yingshuo Wang; Zhimin Chen; Yuanyuan Zhang
Journal:  Front Cell Infect Microbiol       Date:  2021-07-15       Impact factor: 5.293

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.